NCT03375320 2026-04-13Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)Phase 3 Active not recruiting298 enrolled 14 charts 3 FDA
NCT04079712 2026-04-13Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting17 enrolled 12 charts